Changes of fibrinolytic activity in obese diabetics after treatment with Silubin retard.
D001645:Biguanides / Q000494:pharmacology / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity; D010743:Phospholipids / Q000097:blood; D014280:Triglycerides / Q000097:blood
D001645:Biguanides; D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D008055:Lipids; D010743:Phospholipids; D014280:Triglycerides; D002784:Cholesterol